Edwards Lifesciences Corporation
EW
$85.98
-$1.56-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.03% | 1.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.03% | 1.06% | |||
| Cost of Revenue | 5.71% | -0.64% | |||
| Gross Profit | 4.84% | 1.55% | |||
| SG&A Expenses | -13.14% | 16.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.70% | -14.40% | |||
| Total Operating Expenses | -5.32% | 6.17% | |||
| Operating Income | 38.36% | -12.49% | |||
| Income Before Tax | 407.74% | -74.05% | |||
| Income Tax Expenses | 198.85% | -53.30% | |||
| Earnings from Continuing Operations | 492.99% | -78.04% | |||
| Earnings from Discontinued Operations | -- | 1,450.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -100.00% | |||
| Net Income | 317.43% | -68.67% | |||
| EBIT | 38.36% | -12.49% | |||
| EBITDA | 33.98% | -10.68% | |||
| EPS Basic | 318.40% | -68.45% | |||
| Normalized Basic EPS | 30.34% | 4.87% | |||
| EPS Diluted | 329.33% | -69.17% | |||
| Normalized Diluted EPS | 30.31% | 4.79% | |||
| Average Basic Shares Outstanding | -0.21% | -0.74% | |||
| Average Diluted Shares Outstanding | -0.19% | -0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||